Skip to main content
SpringerLink
Log in

A Novel Insulin Sensitizer Drug Candidate—BGP-15—Can Prevent Metabolic Side Effects of Atypical Antipsychotics

  • Research
  • Published:
Pathology & Oncology Research

Abstract

Atypical antipsychotic drugs (AAPD) are widely used to treat severe psychiatric disorders, have well documented metabolic side effects such as disturbances in glucose metabolism, insulin resistance and weight gain. It has been shown that BGP-15, a hydroxylamine derivative with insulin sensitizing activity can prevent AAPD provoked fat accumulation in adipocyte cultures, and insulin resistance in animal experiments and in healthy volunteers. The aim of this study was to compare the preventive effect of BGP-15 with conventional oral antidiabetics on metabolic side effects of AAPDs. We found that BGP-15 that does not belong to either conventional insulin sensitizers or oral antidiabetics, is able to counteract insulin resistance and weight gain provoked by antipsychotic agents in rats while rosiglitazone and metformin were not effective in the applied doses. Our results confirm that BGP-15 is a promising new drug candidate to control the metabolic side effects of atypical antipsychotics. Data indicate that this rat model is suitable to analyze the metabolic side effects of AAPDs and the protective mechanism of BGP-15.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Gardner DM, Baldessarini RJ, Waraich P (2005) Modern antipsychotic drugs: a critical overview. CMAJ 172:1703–1711

    Article  PubMed  Google Scholar 

  2. Dwyer DS, Donohoe D (2003) Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake. Pharmacol Biochem Behav 75:255–260

    Article  PubMed  CAS  Google Scholar 

  3. Cohen T, Sundaresh S, Levine F (2012) Antipsychotics activate the TGFβ pathway effector SMAD3. Molecular Psychiatry. doi:10.1038/mp.2011.186

  4. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 65:267–272

    Article  Google Scholar 

  5. De Hert M, van Eyck D, De Nayer A (2006) Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring. Int Clin Psychopharmacol 21(suppl 2):S11–5

    Article  PubMed  Google Scholar 

  6. Kürthy M, Mogyorósi T, Nagy K, Kukorelli T, Jednákovits A, Tálosi L et al (2002) Effect of BRX-220 against peripheral neuropathy and insulin resistance in diabetic rat models. Ann N Y Acad Sci 967:482–9

    Article  PubMed  Google Scholar 

  7. Literáti-Nagy B, Kulcsár E, Literáti-Nagy Z, Buday B, Pétrfai E, Horváth T, Tory K, Kolonics A, Fleming A, Mandl J, Korányi L (2009) Improvement of insulin sensitivity by a novel drug, BGP-15, in insulin-resistant patients: a proof of concept randomized double-blind clinical trial. Horm Metab Res 41:374–380

    Article  PubMed  Google Scholar 

  8. Tim Crul, Noemi Toth, Stefano Piotto, Peter Literati-Nagy, Kalman Tory, Pierre Haldimann, Bernadett Kalmar, Linda Greensmith, Zsolt Torok, Gabor Balogh, Imre Gombos, Federica Campana, Simona Concilio, Ferenc Gallyas, Gabor Nagy, Zoltan Berente, Burcin Gungor, Maria Peter, Attila Glatz, Akos Hunya, Zsuzsanna Literati-Nagy, Laszlo Vigh Jr., Femke Hoogstra-Berends, André Heeres, Irma Kuipers, Lizette Loen, Jean-Paul Seerden, Deli Zhang, Roelien A M Meijering, Robert H Henning, Bianca JJM Brundel, Harm H Kampinga, Laszlo Koranyi, Zoltan Szilvassy, Jozsef Mandl, Balazs Sumegi, Mark A Febbraio, Ibolya Horvath, Philip L Hooper, Laszlo Vigh (2012) Hydroximic acid derivatives: pleiotrophic HSP coinducers restoring homeostasis and robustness. Curr. Phar. Des (in press).

  9. Gombos I, Crul T, Piotto S, Güngör B, Török Z, Balogh G, Péter M, Slotte PJ, Pilbat AN, Hunya A, Tóth N, Literati-Nagy Z, Vigh L Jr, Glatz A, Brameshuber M, Schütz GJ, Hevener A, Febbraio MA, Horváth I, Vígh L (2011) Membrane-lipid therapy in operation: the HSP co-inducer BGP-15 activates stress signal transduction pathways by remodeling plasma membrane rafts. PLoS One 6(12):e28818

    Article  PubMed  CAS  Google Scholar 

  10. Hargitai J, Lewis H, Boros I, Rácz T, Fiser A, Kurucz I, Benjamin I, Vígh L, Pénzes Z, Csermely P, Latchman DS (2003) Bimoclomol, a heat shock protein co-inducer, acts by the prolonged activation of heat shock factor-1. Biochem Biophys Res Commun 307(3):689–95

    Article  PubMed  CAS  Google Scholar 

  11. Chung J, Nguyen AK, Henstridge DC, Holmes AG, Chan MH, Mesa JL, Lancaster GI, Southgate RJ, Bruce CR, Duffy SJ, Horvath I, Mestril R, Watt MJ, Hooper PL, Kingwell BA, Vigh L, Hevener A, Febbraio MA (2008) HSP72 protects against obesity-induced insulin resistance. Proc Natl Acad Sci USA 105:1739–1744

    Article  PubMed  CAS  Google Scholar 

  12. Literáti-Nagy B, Péterfai E, Kulcsár E, Literáti-Nagy Z, Buday B, Tory K, Mandl J, Sümegi B, Fleming A, Roth J, Korányi L (2010) Beneficial effect of the insulin sensitizer (HSP co-inducer) BGP- 15 on olanzapine-induced metabolic disorders. Brain Res Bull 83:340–344

    Article  PubMed  Google Scholar 

  13. Literáti-Nagy Z, Tory K, Literáti-Nagy B, Kolonics A, Török Z, Gombos I, Balogh G, Vígh L Jr, Horváth I, Mandl J, Sümegi B, Hooper PL, Vígh L (2012) The HSP co-inducer BGP-15 can prevent the metabolic side effects of the atypical antipsychotics. Cell Stress Chaperon. doi:10.1007/s12192-012-0327-5

  14. Ota M, Mori K, Nakashima A, Kaneko YS, Takahashi H, Ota A (2005) Resistance to excessive bodyweight gain in risperidone-injected rats. Clin Exp Pharmacol Physiol 32:279–87

    Article  PubMed  CAS  Google Scholar 

  15. Ota M, Mori K, Nakashima A, Kaneko YS, Fujiwara K, Itoh M, Nagasaka A, Ota A (2003) Peripheral injection of risperidone, an atypical antipsychotic, alters the bodyweight gain of rats. Clin Exp Pharmacol Physiol 30:513–4

    Article  Google Scholar 

  16. Porszasz R, Legvari G, Pataki T, Szilvassy J, Nemeth J, Kovacs P, Paragh G, Szolcsanyi J, Szilvassy Z (2002) Sensory nitrergic nature of the hepatic insulin sensitizing substance mechanism in conscious rabbits. Eur J Pharmacol 17(1–3):211–2, 17

    Article  Google Scholar 

  17. Wallenstein S, Zucker CL, Fleiss JL (1980) Some statistical methods useful in circulation research. Circ Res 47(1):1–9

    Article  PubMed  CAS  Google Scholar 

  18. Cope MB, Nagy TR, Fernández JR, Geary N, Casey DE, Allison DB (2005) Antipsychotic drug-induced weight gain: development of an animal model. Int J Obes 29(6):607–614

    Article  CAS  Google Scholar 

  19. Arulmozhi DK, Dwyer DS, Bodhankar SL (2006) Antipsychotic induced metabolic abnormalities: an interaction study with various PPAR modulators in mice. Life Sci 79(19):1865–72

    Article  PubMed  CAS  Google Scholar 

  20. Panariello F, De Luca V, de Bartolomeis A (2011) Weight Gain, Schizophrenia and Antipsychotics: New Findings from Animal Model and Pharmacogenomic Studies. Schizophrenia Research and Treatment. doi:10.1155/2011/459284

  21. Basu A, Meltzer HY (2006) Differential trends in prevalence of diabetes and unrelated general medical illness for schizophrenia patients before and after the atypical antipsychotic era. Schizophr Res 8:99

    Article  Google Scholar 

  22. Wu R-R, Zhao J-P, Guo X-F, He Y-Q, Fang M-S, Guo W-B, Chen J-D, Li L-H (2008) Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain. A randomized controlled trial. JAMA 299:185

    Article  PubMed  CAS  Google Scholar 

  23. Baptista T, Rangel N, Fernández V, Carrizo E, Fakih Yamily El, Uzcátegui E, Galeazzi T, Gutiérrez MA, Servigna M, Dávila A, Uzcátegui M, Serrano A, Connell L, Beaulieu S, de Baptista EA (2006) Metformin for prevention of weight gain and insulin resistance with olanzapine: A double-blind placebo-controlled trial. Can J Psychiatry 51:192

    PubMed  Google Scholar 

  24. Henderson DC, Fan X, Sharma B, Copeland PM, Borba CP, Boxill R, Freudenreich O, Cather C, Eden Evins A, Goff DC (2009) A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia. Acta Psychiatr Scand 119(6):457–65

    Article  PubMed  CAS  Google Scholar 

  25. Baptista T, Rangel N, El Fakih Y, Uzcátegui E, Galeazzi T, Beaulieu S, Araujo de Baptista E (2009) Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial. Pharmacopsychiatry 42(1):14–9

    Article  PubMed  CAS  Google Scholar 

  26. Wolski K, Steven E (2007) Nissen, Kathy Wolski (2007) Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. N Engl J Med 356:2457–2471

    Article  PubMed  Google Scholar 

  27. Halmosi R, Berente Z, Osz E, Toth K, Literati-Nagy P, Sumegi B (2001) Effect of poly(ADP-ribose) polymerase inhibitors on the ischemia-reperfusion-induced oxidative cell damage and mitochondrial metabolism in Langendorff heart perfusion system. Mol Pharmacol 59:1497–505

    PubMed  CAS  Google Scholar 

  28. Szabados E, Literati-Nagy P, Farkas B, Sumegi B (2000) BGP-15, a nicotinic amidoxime derivate protecting heart from ischemia reperfusion injury through modulation of poly(ADP-ribose) polymerase. Biochem Pharmacol 59:937–45

    Article  PubMed  CAS  Google Scholar 

  29. Zhang D, Ke L, Mackovicova K, Van Der Want JJ, Sibon OC et al (2011) Effects of different small HSPB members on contractile dysfunction and structural changes in a Drosophila melanogaster model for atrial Fibrillation. J Mol Cell Cardiol 51:381–389

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Chemistry, Molecular Biology and Pathobiochemistry Semmelweis University Budapest, Budapest, Hungary

    Zsuzsanna Literati-Nagy & József Mandl

  2. N-Gene Research and Development Ltd, Budapest, Hungary

    Kálmán Tory & Attila Kolonics

  3. Drug Research Center Ltd, Balatonfüred, Hungary

    Botond Literáti-Nagy

  4. Biological Research Center, Hungarian Academy of Sciences, Szeged, Hungary

    László Vígh

  5. Mecsek Pharma Research Ltd, Pécs, Hungary

    László Vígh Jr.

  6. Departments of Pharmacology and Pharmacotherapy, University of Debrecen, 4032, Debrecen, Hungary

    Zoltán Szilvássy

Authors
  1. Zsuzsanna Literati-Nagy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kálmán Tory
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Botond Literáti-Nagy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Attila Kolonics
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. László Vígh Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. László Vígh
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. József Mandl
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zoltán Szilvássy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kálmán Tory.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Literati-Nagy, Z., Tory, K., Literáti-Nagy, B. et al. A Novel Insulin Sensitizer Drug Candidate—BGP-15—Can Prevent Metabolic Side Effects of Atypical Antipsychotics. Pathol. Oncol. Res. 18, 1071–1076 (2012). https://doi.org/10.1007/s12253-012-9546-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-012-9546-4

Keywords

Search

Navigation